Hong Kong – 18 June 2026 – Kintor Pharmaceutical Limited (“Kintor Pharma”) announced that every resolution tabled at today’s annual general meeting (AGM) was approved by poll.

Key voting data • Issued share capital: 498.66 million shares • Shares abstained (employee incentive scheme): 5.03 million • Shares entitled to vote: 493.63 million

Voting turnout reached 107.61 million shares, all cast in person or by proxy.

Principal resolutions and results 1. FY2025 audited financial statements and directors’ and auditor’s reports were adopted with 100.00 % of votes in favour.

2. Board composition was reaffirmed: – Executive Director Dr. Xiang Ni, Non-executive Director Mr. Yunfei Chen and Independent Non-executive Director Ms. Geqi Wei were each re-elected with 100.00 % support. – The Board was authorised to determine directors’ remuneration (100.00 % in favour).

3. Rongcheng (Hong Kong) CPA Limited was appointed as external auditor until the next AGM, receiving 99.70 % approval.

4. Capital management mandates were renewed: – General mandate to issue up to 20 % of existing share capital: 99.70 % approval. – Share buy-back mandate for up to 10 % of outstanding shares: 100.00 % approval. – Extension mandate allowing re-issuance of repurchased shares: 99.70 % approval.

Governance notes • No shareholders were required to abstain beyond the 5.03 million shares held by Kiya Company Limited, trustee for the employee incentive scheme. • Computershare Hong Kong Investor Services Limited acted as scrutineer. • All directors attended the meeting, chaired by Dr. Youzhi Tong.

With all ordinary resolutions passed, Kintor Pharma retains full authority for routine capital activities and enters the 2026 financial year with an unchanged board and auditor.